Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status

Resuscitation

Volumn 84, Issue 3, 2013, Pages 384-390

  Vaillant, Fanny ^a   Dehina, Leila ^a   Dizerens, Nicole ^a   Bui Xuan, Bernard ^a   Tabib, Alain ^b   Lauzier, Benjamin ^c   Chevalier, Philippe ^a,d   Descotes, Jacques ^a,e   Timour, Quadiri ^a,e  

^a University Claude Bernard Lyon 1   (France)

^b UNIVERSITÉ LYON 1   (France)

^c L INSTITUT DU THORAX   (France)

^d LOUIS PRADEL HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

Acute coronary syndrome; Heart rate reduction; Myocardial energetic status; Resuscitation; Ventricular fibrillation

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; IVABRADINE; PROPRANOLOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; HEART ATRIUM PACING; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART RATE; HEART VENTRICLE FIBRILLATION; HIGH ENERGY PHOSPHATE; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PROPRANOLOL; RESUSCITATION; SWINE; VENTRICULAR FIBRILLATION;

EID: 84875055007     PISSN: 03009572     EISSN: 18731570     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2012.07.041     Document Type: Article

References (31)

1. Roelandt J., Klootwijk P., Lubsen J., Janse M.J. Sudden death during longterm ambulatory monitoring. Eur Heart J 1984, 5:7-20.
2. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989, 69:1049-1169.
3. Palatini P., Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997, 11(Suppl. 1):S19-S27.
4. Palatini P., Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997, 15:3-17.
5. Palatini P. Elevated heart rate: a " new" cardiovascular risk factor?. Prog Cardiovasc Dis 2009, 52:1-5.
6. Aupetit J.F., Timour Q., Loufoua-Moundanga J., et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 1995, 25:810-816.
7. Bui-Xuan B., Aupetit J.F., Freysz M., Loufoua J., Faucon G., Timour Q. Cardiac beta-adrenoreceptor activation and ventricular fibrillation under normal and ischemic conditions. Cardiovasc Res 1996, 32:1056-1063.
8. Bohm M., Swedberg K., Komajda M., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010, 376:886-894.
9. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
10. Aupetit J.F., Frassati D., Bui-Xuan B., Freysz M., Faucon G., Timour Q. Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration. Cardiovasc Res 1998, 37:646-655.
11. Vaillant F., Timour Q., Descotes J., et al. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmacol 2008, 52:548-554.
12. Vaillant F., Dehina L., Mazzadi A., et al. Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: role of myocyte structure and myocardial perfusion. Resuscitation 2011, 82:1092-1099.
13. Ceconi C., Cargnoni A., Francolini G., Parinello G., Ferrari R. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res 2009, 84:72-82.
14. Gazmuri R.J., Ayoub I.M., Kolarova J.D., Karmazyn M. Myocardial protection during ventricular fibrillation by inhibition of the sodium-hydrogen exchanger isoform-1. Crit Care Med 2002, 30(Suppl.):S166-S171.
15. Angelos M.G., Griffith R.F., Beckley P.D., Rath D.P., Little C.M. Myocardial metabolic changes during reperfusion of ventricular fibrillation: a 31P nuclear magnetic resonance study in swine. Crit Care Med 1995, 23:733-739.
16. Angelos M.G., Torres C.A., Waite M.D., et al. Left ventricular myocardial adenosine triphosphate changes during reperfusion of ventricular fibrillation: the influence of flow and epinephrine. Crit Care Med 2000, 28:1503-1508.
17. Lauzier B., Vaillant F., Gelinas R., et al. Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts. Am J Physiol Heart Circ Physiol 2011, 300:H845-H852.
18. Ceconi C., Comini L., Suffredini S., et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 2011, 300:H366-H373.
19. Scolletta S., Biagioli B. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed Pharmacother 2010, 64:203-207.
20. Jennings R.B., Reimer K.A. The cell biology of acute myocardial ischemia. Annu Rev Med 1991, 42:225-246.
21. Neumar R.W., Brown C.G., Robitaille P.M., Altschuld R.A. Myocardial high energy phosphate metabolism during ventricular fibrillation with total circulatory arrest. Resuscitation 1990, 19:199-226.
22. Kloner R.A., Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001, 104:3158-3167.
23. Kloner R.A., Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 2001, 104:2981-2989.
24. Jennings R.B., Murry C.E., Steenbergen C., Reimer K.A. Development of cell injury in sustained acute ischemia. Circulation 1990, 82(Suppl.):II2-II12.
25. Jennings R.B., Reimer K.A., Jones R.N., Peyton R.B. High energy phosphates, anaerobic glycolysis and irreversibility in ischemia. Adv Exp Med Biol 1983, 161:403-419.
26. Wu F., Zhang E.Y., Zhang J., Bache R.J., Beard D.A. Phosphate metabolite concentrations and ATP hydrolysis potential in normal and ischaemic hearts. J Physiol 2008, 586:4193-4208.
27. Liu J., Wang C., Murakami Y., et al. Mitochondrial ATPase and high-energy phosphates in failing hearts. Am J Physiol Heart Circ Physiol 2001, 281:H1319-H1326.
28. Vogt A.M., Elsasser A., Pott-Beckert A., et al. Myocardial energy metabolism in ischemic preconditioning and cardioplegia: a metabolic control analysis. Mol Cell Biochem 2005, 278:223-232.
29. Schaefer S., Schwartz G.G., Gober J.R., et al. Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia. Phosphorus-31 nuclear magnetic resonance studies of porcine myocardium in vivo. J Clin Invest 1990, 85:706-713.
30. Neubauer S. Influence of left ventricular pressures and heart rate on myocardial high-energy phosphate metabolism. Basic Res Cardiol 1998, 93(Suppl. 1):102-107.
31. Zhang J., Liem D.A., Mueller M., et al. Altered proteome biology of cardiac mitochondria under stress conditions. J Proteome Res 2008, 7:2204-2214.